EP Patent

EP2081574A1 — Buprenorphine-containing non-pressurised spray composition for transmucosal administration

Assigned to Pharmasol Ltd · Expires 2009-07-29 · 17y expired

What this patent protects

There is provided according to the invention a non-pressurised pharmaceutical liquid solution spray composition comprising: (i) buprenorphine; and 5 (ii) a solvent comprising ethanol which composition is substantially free of chloride.

USPTO Abstract

There is provided according to the invention a non-pressurised pharmaceutical liquid solution spray composition comprising: (i) buprenorphine; and 5 (ii) a solvent comprising ethanol which composition is substantially free of chloride.

Drugs covered by this patent

Risperdal (risperidone) · Johnson & Johnson (Janssen)

Patent Metadata

Patent number: EP2081574A1
Jurisdiction: EP
Classification: —
Expires: 2009-07-29
Drug substance claim: No
Drug product claim: No
Assignee: Pharmasol Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.